<SEC-DOCUMENT>0001628280-23-027935.txt : 20230808
<SEC-HEADER>0001628280-23-027935.hdr.sgml : 20230808
<ACCEPTANCE-DATETIME>20230808070920
ACCESSION NUMBER:		0001628280-23-027935
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230808
DATE AS OF CHANGE:		20230808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			C4 Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001662579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475617627
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39567
		FILM NUMBER:		231149278

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 120
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(617) 231-0700

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 120
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cccc-20230808.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:e41e5b28-c38f-4f23-b803-bd982ad1d05e,g:d2847133-230f-43be-87fb-4260419de6ee,d:fb4800d94b32416297bca93c85bff77c--><html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cccc-20230808</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001662579</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cccc-20230808.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifb4800d94b32416297bca93c85bff77c_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 8, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">C4 THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:32.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39567</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-5617627</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">490 Arsenal Way,</ix:nonNumeric>&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 120</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Watertown,</ix:nonNumeric>&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02472</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">231-0700</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:4.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:38.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">CCCC</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#212529;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#212529;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div></div><div id="ifb4800d94b32416297bca93c85bff77c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, C4 Therapeutics, Inc. (the &#8220;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issued a press release announcing its financial results and business highlights for the quarter ended June 30, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="ifb4800d94b32416297bca93c85bff77c_16"></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:7.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">99.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cccc-20230808xexx991.htm">Press release issued August 8, 2023</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div></div><div id="ifb4800d94b32416297bca93c85bff77c_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:47.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">C4 Therapeutics, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Date: </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">August 8, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">/s/ Lauren A. White</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Lauren A. White</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Chief Financial Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cccc-20230808xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4770db3470dd493cac2a29d753b11c0f_1"></div><div style="min-height:45.36pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:6pt"><img alt="c4tlogo.jpg" src="c4tlogo.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:187px"></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights</font></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC&#8482; Degrader, with Betta Pharmaceuticals in Greater China for NSCLC&#59; U.S. IND Cleared </font></div><div style="margin-bottom:0.08pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Ongoing Phase 1&#47;2 Clinical Trials of CFT7455, an IKZF1&#47;3 MonoDAC&#8482; Degrader, and CFT8634, a BRD9 BiDAC Degrader, Continue to Progress&#59; Phase 1 Dose Escalation Data Expected 2H 2023 </font></div><div style="margin-bottom:0.08pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Strengthened Leadership Team with Appointments of Len Reyno, M.D., as Chief Medical Officer, and Mary Christian, Pharm.D., as Senior Vice President, Regulatory  </font></div><div style="margin-bottom:0.08pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Marketable Securities Total $286.7 million as of June 30, 2023&#59; Expected to Provide Runway into 2H 2025 </font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WATERTOWN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq&#58; CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the second quarter ended June 30, 2023, as well as recent business highlights. </font></div><div style="margin-bottom:0.08pt;margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;In the first half of 2023, we achieved important objectives to support the continued advancement of our degrader medicine portfolio.&#8239;We completed an exclusive licensing agreement with Betta Pharmaceuticals to develop CFT8919, our EGFR-L858R degrader, in Greater China, strengthened our leadership team, and progressed three clinical studies across multiple cancer indications,&#8221; said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. &#8220;In the second half of the year, we expect to share clinical updates from the dose escalation portion of the ongoing Phase 1&#47;2 trials for our two lead programs, CFT7455 in multiple myeloma and CFT8634 in synovial sarcoma and SMARCB1-null cancers.&#8221; </font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECOND QUARTER 2023 AND RECENT ACHIEVEMENTS </font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CFT7455&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> CFT7455 is an oral degrader of IKZF1&#47;3 for the treatment of multiple myeloma (MM) and non-Hodgkin&#8217;s lymphomas (NHL).</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Progressed the Phase 1&#47;2 Clinical Trial&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The dose escalation portion of the CFT7455 Phase 1&#47;2 clinical trial continues in MM and NHL. The three arms of the trial are evaluating CFT7455 as a monotherapy for MM, in combination with dexamethasone for MM and as a monotherapy for NHL.</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:12.53pt">Presented New Preclinical Data at the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">International Conference on Malignant Lymphoma</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">ICML)&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In June 2023, C4T presented preclinical CFT7455 data in NHL demonstrating potent anti-tumor activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents.</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CFT8634&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CFT8634 is an oral degrader of BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Progressed the Phase 1&#47;2 Clinical Trial&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The dose escalation portion of the CFT8634 Phase 1&#47;2 clinical trial continues in synovial sarcoma and SMARCB1-null solid tumors. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Initiated the first enrichment cohort&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In August, C4T initiated the first enrichment cohort to further assess pharmacodynamic and safety data. This planned additional cohort further helps support enrollment demand for the ongoing dose escalation portion of the CFT8634 Phase 1&#47;2 clinical trial.</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CFT1946&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> CFT1946 is an oral degrader targeting BRAF V600 mutations for the treatment of solid tumors including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and melanoma.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Progressed the Phase 1&#47;2 Clinical Trial&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The dose escalation portion of the CFT1946 Phase 1&#47;2 clinical trial continues in V600 solid tumors, including NSCLC, CRC, and melanoma. Trial sites are now open and enrolling patients in the U.S. and Europe.</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:14.15pt">Presented Trial in Progress Poster at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> In June 2023, C4T presented a trial in progress poster titled &#8220;A Phase 1&#47;2 Study of CFT1946, A Novel Bifunctional Degradation Activating Compound, or BiDAC Degrader, of Mutant BRAF V600 as Monotherapy and in Combination with Trametinib, in Mutant BRAF V600 Solid Tumors.&#34;</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CFT8919&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CFT8919 is an oral degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC). </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Exclusive Licensing Agreement with Betta Pharmaceuticals in Greater China&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In May 2023, C4T entered into an exclusive license and collaboration agreement for the development and commercialization of CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan. C4T expects to receive a total of $35.0 million, which includes $10.0 million in upfront cash paid in June 2023 under the collaboration agreement and a $25.0 million one-time equity investment under the stock purchase agreement. Additionally, C4T is eligible for up to $357.0 million in potential milestones and low to mid-double-digit percent royalties on net sales in the licensed territories. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Investigational New Drug (IND) Application Clearance Achieved&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In June 2023, the U.S. Food and Drug Administration (FDA) cleared C4T&#8217;s IND application for CFT8919. C4T expects to initiate clinical trial activities outside Greater China following the completion of Betta Pharmaceuticals&#8217; Phase 1 dose escalation study in Greater China.</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CORPORATE UPDATES</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In July 2023, C4T appointed two new senior leaders. Leonard (Len) Reyno, M.D., joined C4T as chief medical officer with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials. Mary Christian, Pharm.D. joined C4T as senior vice president, regulatory with more than two decades of experience in regulatory and drug development.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UPCOMING KEY MILESTONES</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">CFT7455&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Present Phase 1 dose escalation data from the Phase 1&#47;2 clinical trial of Arm B1, evaluating CFT7455 as a monotherapy in MM, in the second half of 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">CFT8634&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Present Phase 1 dose escalation data from the Phase 1&#47;2 clinical trial for synovial sarcoma and SMARCB1-null solid tumors in the second half of 2023.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">   </font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECOND QUARTER 2023 FINANCIAL RESULTS</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022. The decrease in revenue was due to a reduction of revenue recognized for research activities under the Biogen and Calico collaborations. Total revenue for the second quarter of 2023 reflects revenue recognized under collaboration agreements with Roche and Biogen, and total revenue recognized in the second quarter of 2022 reflects revenue recognized under collaborations agreements with Roche, Biogen, and Calico. </font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development (R&#38;D) Expense&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;R&#38;D expense for the second quarter of 2023 was $29.9 million, compared to $31.3 million for the second quarter of 2022. The reduction in R&#38;D expense was primarily attributable to a decrease in IND-enabling activities as programs transition to the clinic.</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General and Administrative (G&#38;A) Expense&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;G&#38;A expense for the second quarter of 2023 was $10.3 million, compared to $9.9 million for the second quarter of 2022. The higher G&#38;A expense was attributable to a slight increase in professional fees.  </font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss and Net Loss per Share&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Net loss for the second quarter of 2023 was $35.9 million, compared to $27.4 million for the second quarter of 2022. Net loss per share for the second quarter of 2023 was $0.73 compared to $0.56 for the second quarter of 2022.</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Position and Financial Guidance&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Cash, cash equivalents and marketable securities as of June 30, 2023, were $286.7 million, compared to $337.1 million as of December 31, 2022. The decrease in cash was primarily driven by expenditures to fund operations, partially offset by the $10.0 million upfront payment received from Betta Pharmaceuticals. C4T expects that its cash, cash equivalents and marketable securities </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as of June 30, 2023, along with the anticipated equity investment from an affiliate of Betta Pharmaceuticals, will be sufficient to fund planned operating expenses and capital expenditures into the second half of 2025.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About C4 Therapeutics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br>C4 Therapeutics (C4T) (Nasdaq&#58; CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients&#8217; lives. C4T is leveraging its TORPEDO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;platform to efficiently design and optimize small-molecule medicines that harness the body&#8217;s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.c4therapeutics.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About CFT7455</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CFT7455 is an orally bioavailable MonoDAC&#8482; degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3). CFT7455 binds with high affinity to the E3 ligase adapter protein, cereblon, to target and degrade IKZF1&#47;3 for the treatment of multiple myeloma and non-Hodgkin's lymphomas, including peripheral T cell lymphoma and mantle cell lymphoma. In early clinical data, CFT7455 demonstrated deep and durable degradation of IKZF1&#47;3. C4T is enrolling patients in its ongoing Phase 1&#47;2 clinical trial of CFT7455. More information about this trial may be accessed at www.clinicaltrials.gov (identifier&#58; NCT04756726).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About CFT8634</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CFT8634 is an orally bioavailable BiDAC&#8482; degrader designed to be potent and selective against BRD9. BRD9 was previously considered an undruggable target due to the inability of bromodomain inhibitors to effectively treat cancers dependent on BRD9. Unlike BRD9 inhibition, BRD9 degradation has been shown to be efficacious in pre-clinical models of synovial sarcoma. C4T is enrolling patients in its ongoing Phase 1&#47;2 clinical trial of CFT8634 for the treatment of synovial sarcoma and SMARCB1-null solid tumors. More information about this trial may be accessed at www.clinicaltrials.gov (identifier&#58; NCT05355753).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About CFT1946</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CFT1946 is an orally bioavailable BiDAC&#8482; degrader designed to be potent and selective against BRAF V600 mutant targets. In preclinical studies, CFT1946 is active&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;and&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. C4T is advancing CFT1946 to the clinic to study treatment for BRAF V600 mutant solid tumors including non-small cell lung cancer, colorectal cancer, and melanoma. C4T is enrolling patients in its ongoing Phase 1&#47;2 clinical trial of CFT1946. More information about this trial may be accessed at www.clinicaltrials.gov (identifier&#58; NCT05668585).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About CFT8919</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CFT8919 is an orally bioavailable allosteric BiDAC&#8482; degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;models of L858R driven non-small cell lung cancer. Importantly, in preclinical studies, CFT8919 retains full activity against additional EGFR mutations that confer resistance against approved EGFR inhibitors including L858R-C797S, L858R-T790M, and&#160;L858R-T790M-C797S. In 2023, C4T and Betta Pharmaceuticals entered into an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains &#8220;forward-looking statements&#8221; of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients&#59; the design and potential efficacy of our therapeutic approaches&#59; the predictive capability of our TORPEDO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;platform in the development of novel, selective, orally bioavailable BiDAC&#8482; and MonoDAC&#8482; degraders&#59; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">other clinical development activities including clinical trial commencement&#59; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials&#59; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials&#59; regulatory developments in the United States and foreign countries&#59; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to&#58; uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates&#59; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized&#59; the risk that the results of preclinical studies and&#47;or clinical trials will or will not be predictive of results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in C4 Therapeutics&#8217; most recent Annual Report on Form 10-K and&#47;or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.</font></div><div style="margin-bottom:8pt;margin-top:6pt"><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Condensed Consolidated Balance Sheet Data</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">(in thousands)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.937%"><tr><td style="width:1.0%"></td><td style="width:69.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">June 30,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">286,700&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">337,115&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">375,008&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">430,840&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">38,618&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">33,513&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term debt - related party</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,335&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,482&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#14232c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">233,707&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">289,234&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i4770db3470dd493cac2a29d753b11c0f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Condensed Consolidated Statement of Operations</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">(in thousands, except share and per share amounts)</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revenue from collaboration agreements</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,664&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">13,834&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,423&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21,488&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">29,926&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31,323&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">58,968&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">57,526&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,306&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,895&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21,251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">22,715&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total operating expenses</font></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">40,232&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">41,218&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">80,219&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">80,241&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(37,568)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(27,384)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(73,796)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(58,753)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense and amortization of long-term debt &#8722; related party</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(600)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(534)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,206)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,061)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest and other income, net</font></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,246&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">506&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,300&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">782&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,646&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(28)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,094&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(279)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(35,922)</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(27,412)</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(70,702)</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(59,032)</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss per share &#8722; basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.73)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.56)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1.44)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1.21)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted-average number of shares used in computed net loss per share &#8722; basic and diluted</font></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,063,631&#160;</font></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">48,823,698&#160;</font></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,048,062&#160;</font></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">48,779,508&#160;</font></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other comprehensive loss&#58;</font></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Unrealized gain (loss) on marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">696&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(931)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,363&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,806)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Comprehensive loss</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(35,226)</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(28,343)</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(68,339)</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(62,838)</font></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Contacts&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Investors&#58;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Courtney Solberg</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Senior Manager, Investor Relations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><br></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">CSolberg&#64;c4therapeutics.com</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Media&#58;&#160;<br>Loraine Spreen&#160;<br>Senior Director, Corporate Communications &#38; Patient Advocacy&#160;<br></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">LSpreen&#64;c4therapeutics.com</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cccc-20230808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e41e5b28-c38f-4f23-b803-bd982ad1d05e,g:d2847133-230f-43be-87fb-4260419de6ee-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cccc="http://c4therapeutics.com/20230808" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://c4therapeutics.com/20230808">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cccc-20230808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cccc-20230808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://c4therapeutics.com/role/CoverPageDocument">
        <link:definition>0000001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cccc-20230808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e41e5b28-c38f-4f23-b803-bd982ad1d05e,g:d2847133-230f-43be-87fb-4260419de6ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_97c36703-4abd-4054-a4a5-fd7ac2de51ad_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fbe6ced9-42e5-4091-b63f-9c836e5ea07b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3f4b0e14-acb1-4e24-afa9-c2d5f2d39f4f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_75f775b1-7f41-4c3c-832c-6d2ad167145c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3af998ad-be25-49ca-8753-430f6a6f2bb6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_62d61c65-e3d4-4e2c-80a3-59284753759a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_57e3bab6-e9cb-4fc0-a270-707b299547ef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_6c75370d-c15b-487b-8bec-7838693129d5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8d66dc00-eb65-4981-ab35-832bb28874b0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_df00ed4f-2306-42db-a4da-03bd7aa44024_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_de56377c-924d-474f-8608-733bfb63dc65_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_01cd418e-9a3d-4be7-b179-4a0faa1437f9_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_909409af-5806-4816-8cdc-4ad327dd3872_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_252031c5-23b8-4f56-99e3-bf582785b793_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b2cc8c77-3a73-4d9a-8387-45a3b086062d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e5ea16a9-b10f-4432-8cc8-72d93e1276bd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f4e075c7-2ea9-4b86-bf29-03bb5c62415f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2ea4c719-9116-40b7-a752-b76450fd2a1c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0a7fb590-1f87-41c6-a2b6-5173a2aefab2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ae744c1f-00d5-4087-be08-d9f9e602be69_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_47d2d313-fc62-427f-9bbb-5b8085d7d610_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_90181196-2df2-4f65-9b24-062d165dd649_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a193886b-a596-4d77-926e-151a31ca0a28_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cccc-20230808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e41e5b28-c38f-4f23-b803-bd982ad1d05e,g:d2847133-230f-43be-87fb-4260419de6ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://c4therapeutics.com/role/CoverPageDocument" xlink:type="simple" xlink:href="cccc-20230808.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://c4therapeutics.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c22a21f8-d813-4816-944d-810ce75c62a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_DocumentType_c22a21f8-d813-4816-944d-810ce75c62a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a797096a-1f23-4c0e-ac77-0cf63a36cb7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_DocumentPeriodEndDate_a797096a-1f23-4c0e-ac77-0cf63a36cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bca96fe2-bfcf-4d5a-a438-9a7db89886c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityRegistrantName_bca96fe2-bfcf-4d5a-a438-9a7db89886c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_217de181-8928-454a-b1a5-b92d15246349" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_217de181-8928-454a-b1a5-b92d15246349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_55715783-7451-4646-a7af-5e49c8831357" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityFileNumber_55715783-7451-4646-a7af-5e49c8831357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_da67500c-15e8-4b54-ab6a-f6bf9e0f18ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityTaxIdentificationNumber_da67500c-15e8-4b54-ab6a-f6bf9e0f18ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9822c489-d8f8-4d0f-a891-1dc0fce8b7cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityAddressAddressLine1_9822c489-d8f8-4d0f-a891-1dc0fce8b7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_28f57d76-1697-4968-a83f-84c1b7ffd11e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityAddressAddressLine2_28f57d76-1697-4968-a83f-84c1b7ffd11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_967edc40-d360-4146-a9df-a1ae3d389a30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityAddressCityOrTown_967edc40-d360-4146-a9df-a1ae3d389a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_594ca633-e105-414b-a0a0-937ea895240d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityAddressStateOrProvince_594ca633-e105-414b-a0a0-937ea895240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ed03f345-91ab-4c90-84b8-11a807ac5501" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityAddressPostalZipCode_ed03f345-91ab-4c90-84b8-11a807ac5501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0132d0d5-dc7d-42ba-b315-e98f68f6cced" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_CityAreaCode_0132d0d5-dc7d-42ba-b315-e98f68f6cced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_50c5a1ee-e942-4aaf-a6cc-3e52ef081010" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_LocalPhoneNumber_50c5a1ee-e942-4aaf-a6cc-3e52ef081010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4e6a7556-d00d-4311-885d-684a61e34120" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_WrittenCommunications_4e6a7556-d00d-4311-885d-684a61e34120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_130aa336-ada2-442c-bd87-0f5dcc84d87a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_SolicitingMaterial_130aa336-ada2-442c-bd87-0f5dcc84d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0e99e978-00ca-4aec-b556-554c53350429" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_PreCommencementTenderOffer_0e99e978-00ca-4aec-b556-554c53350429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3e35f399-3094-4247-a0e5-0f8a4453efc4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3e35f399-3094-4247-a0e5-0f8a4453efc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f6a23a1e-b341-41ae-8a50-57a21dd09702" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_Security12bTitle_f6a23a1e-b341-41ae-8a50-57a21dd09702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6cefde6e-f364-490e-b9ca-5f7a9be5cc3f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_TradingSymbol_6cefde6e-f364-490e-b9ca-5f7a9be5cc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af525de8-ce1a-4538-87dd-fe0958e6c5a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_SecurityExchangeName_af525de8-ce1a-4538-87dd-fe0958e6c5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3ce1e67d-e296-41cb-918e-91d466f0e8d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityEmergingGrowthCompany_3ce1e67d-e296-41cb-918e-91d466f0e8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ed02dbf6-f33c-4d87-88e9-412a96f30243" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_EntityCentralIndexKey_ed02dbf6-f33c-4d87-88e9-412a96f30243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e4578186-4cec-495b-8e7b-6469636fe845" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b99f4606-8f30-4969-bc19-b807a6f5c22c" xlink:to="loc_dei_AmendmentFlag_e4578186-4cec-495b-8e7b-6469636fe845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>c4tlogo.jpg
<TEXT>
begin 644 c4tlogo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !  :D# 2(  A$! Q$!_\0
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M?XM?#=/"OA^_L4O]'V26,,4ZLL6Q=FQ@,D J2OL<9Z5\=Q_LK_$JXUK^SO\
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MK-T#Q)IGBG3_ +=I-[%?VFXIYL1R-PQD?J*TJ "BBB@ HHHH **** "BBB@
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M_(@>(O\ KPF_] - 'D/[//C31? OP/BO];OH[*W-[,J[LEG;"G"J.2:W]/\
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M\40C6?$.K,;I7ODW"!=V5*J1P3@'/I@#%>J>)/A_X=\7:>UGJVCVEW!SMW1
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M#?VT+?*V1E947)(1L$8/0JPR<9K\N]6\-ZII.K-IEYI]S;:@K[#;21,)-Q.
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MT\!60ML%P@/ STR!D8/!!Q0!E?\ #.?BG_HK6O?^1O\ X_6-XN^ =WI^BO\
M\)+\8-1BTJ9EC<:AO\IV^\%(:?!/RY_"MF']H[6M!ACM/$W@35H-5507^RH3
M&PQ]X9'&3GCFL>_\(^./V@O$%@_B73W\+^#[1_-^QLQ$LW0]."21QD@!<GOP
M0#>^,&FVNC_LN_8;*]74K.VM+"*&\C&%F198@' R>".>IZUZ7\+_ /DFOA7_
M +!5K_Z*6N<^/OAV[UCX/:KI6D64EU<'[.L5O F3M6:,G 'H 3^%=3\.[.?3
M_ /ANUNHF@N8=.MXY8I!AD81J"#[@T >+^+KAM#_ &LO#UU=6N;:]M5@AFD
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M%%%>@>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X5\+_^3C/B/_US3^:5[K7(^'_AKI_AWQQKOBB"YN9+S5U5989"OEIC
M'W<#/8=2:ZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140549191757888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">C4 THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5617627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">490 Arsenal Way,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">231-0700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CCCC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001662579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>cccc-20230808_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cccc-20230808.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001662579</identifier>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001662579</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">C4 THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39567</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-5617627</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">490 Arsenal Way,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 120</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Watertown,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">231-0700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">CCCC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MB=P.'=\YGGCAZXVQ)]S1(*-K-F?F2S93,')+E9BG3&@N!5%L-71"_^X^Z-J
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MK;3.K91[#Z]DRS'P^%G+'U!+ P04    "  I.0A7)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ *3D(5V60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M"  I.0A7!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( "DY"%>71\]E[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "DY"%>97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ *3D(5[=XJ71C!   +1$  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "DY"%>?H!OP
ML0(  .(,   -              "  :8,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ *3D(5Y>*NQS     $P(   L              ( !@@\  %]R96QS
M+RYR96QS4$L! A0#%     @ *3D(5]M?!^TY 0  , (   \
M ( !:Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "DY"%<D'INBK0
M /@!   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( "DY"%=ED'F2&0$  ,\#   3              "
M ;82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(    4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cccc-20230808.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cccc-20230808.htm">cccc-20230808.htm</File>
    <File>cccc-20230808.xsd</File>
    <File>cccc-20230808_lab.xml</File>
    <File>cccc-20230808_pre.xml</File>
    <File>cccc-20230808xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cccc-20230808.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "cccc-20230808.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cccc-20230808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cccc-20230808_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cccc-20230808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cccc",
   "nsuri": "http://c4therapeutics.com/20230808",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cccc-20230808.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page Document",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://c4therapeutics.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cccc-20230808.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-027935-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-027935-xbrl.zip
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M&O/89VT'?C3D *-A-$Y+Z9>GI71J.W1G[5.77Q,9SWQV5G"YC'PZ:P5AP
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M1$ZC/A\%+0>HS01,%E/;9_D .Q2 I.:$OD\CR5KY'R>Y7*;Z1U.#3E:A0SS
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M[CF**5=I5RNT*W6M6C/K->M^XCU>K'WFW=*D<QKNQVSMR1BKE-:1$EMTZ2_
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MC6/J(-6 _QE0:NV DLV6"0N#Y9CZOO*CH,EEX)ZYN8QXW&=NQBEJ8\'K 6/
ME-Z8>SV-K8.. Q&_9> .0@:!LB$&E3?@@A*9V/_%,%HQ.2,^IS;W4ZHJ.M.8
MR)3T1=@UD>T?7]X^/K^>!1_ FYZ__H7<A4YO=A3MSD,L>0@:WB[#%3'SR")U
M:YQ-E>CB.3<6(X. 3PW+R?0RN;.ZKDP<\+BSI3?(YY;6OU8X *&^Q[PV=<-<
M,J+JU@*6/^6RI,I#UT]'[O&C8I8] I&Z32YSLFN&+<6MV LE."7C2TJOCAX&
MB$ *22:&"QG,5"UJ4!2CN<XM0H<(M+$Z"AIDH:W/KE42"1E(X)N+0H6=B<KS
MJP6*2G0A)!4NOMVX>#IT<2P4I5:Q8 TX,'WA(?%3\S( 0S$OGUM-'7H<*W[L
M!1!3)ZDB_T6WYI85+=,N//I: L>Z;FU9%'WY"FZCJ3>KY7U4<&WJ?!T)\.=<
M+9,.3_W<E]1^9<7,3",<>C$SO:*Q=27SP8W;IK#QB,T_O-KG.R8=P:.5^_%/
MX?PGE'ONE8R7J/>@V[]%,>Q9F>FYZ*DDY ZB>M[S$-6XW_DXI0<#"]GP#/"4
M3:?-IJF/XXDZA+<26JM8?_W],KKINNRW-BDO(3BF47EIN7E-Y.J$  VYI! (
M]M ^4$==AWU'8YJ^D''$P+JY;O:R/4^]VYYR]HAZ =_-7N#;Y=CFVTI>-U]Q
M\OI%;X .>A_ZY\//5_<\8GP8H?/RZYUI=(?Q7)8#V"Y35MQ4\703?T8<FF"5
M4L5HZ4.86: I88,PT@Q4NM9F$(UZF(O!B92]R#I@FHDE 0Q2\]$D'H<"L'/?
M8K17J>M&L[+WP,S2J^;^[RHJ8&O?)-R[TV#5WIC!VE0%VA0^K-D:LWI?>?A;
MN -[G^,%,P1W&Z1OS0_XWF^+O%#24$&P[GKO*P]P\+>!?IFU]N%JOP:M4Y(E
M\I$F@@7D7"=?QCQF>TE9'(I^>9VID\UII;>\3Z]I'SICSKRELEGZQ))0-8HA
M1$82MDF\K:"QE/Y76.K_SVK_'U!+ P04    "  I.0A7,ST557D"  "<!P
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MK#=I:Z,7>3V$X>X4KMZW)M495N,_'3P!4$L#!!0    ( "DY"%?%2P6QC H
M !-A   5    8V-C8RTR,#(S,#@P.%]L86(N>&ULU5Q=;]LX%GWOK]!F7W:!
M82U^2)2*MH-NIAT4FVF#)L4,=K$P^*5$J"T%LM(D_WY)V4ZD6+))R5;=E\2Q
MKR[//=&YO)>D_/K7^_G,^ZZ*19IG;T[@2__$4YG(99I=O3GY>OD!1">_OGWQ
MXO7? /CK7U_.O-]R<3M76>F=%HJ52GIW:7GME=?*^S,OOJ7?F7<^8V62%W,
MWE:7G>8W#T5Z=5UZR$=X;;;^M'BE"%0!1Q$0.$H 21 &//+U#QE'B$DH_4#]
M<O5*HHA0B#% V-=FF"L0T80#@D*?P%BJ4*G*Z2S-OKTR/SA;*$^'ERVJ/]^<
M7)?ES:O)Y.[N[N4]+V8O\^)J@GP?3];6)ROS^PW[.UQ9PSB.)]6GCZ:+M,U0
MNX63O_XXNQ#7:LY FBU*E@DSP")]M:C>/,L%*RO6=^+R.BW,7V!M!LQ; "*
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M/LJ# 3S=\Z/('QU4RM5Q! _T?2\"6 (86_VJIEB<2+T=^>,#G"02/Z(2=^7
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MFI?&4N*^#)/-XJ9:*U?KB(RO6;4M[MRY*9_I95:P'(G7]RO>A$]G%Y+J<=+
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MI;EZ:6&ZM*1__&)O?7VU!KJ/NH1T)#@=G=(]A+X&V$YCYGJ34YD<&F67@E(
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M;QB-W-_^'U!+ 0(4 Q0    ( "DY"%<:"9@Z7 \  #IN   1
M  "  0    !C8V-C+3(P,C,P.# X+FAT;5!+ 0(4 Q0    ( "DY"%<S/155
M>0(  )P'   1              "  8L/  !C8V-C+3(P,C,P.# X+GAS9%!+
M 0(4 Q0    ( "DY"%?%2P6QC H  !-A   5              "  3,2  !C
M8V-C+3(P,C,P.# X7VQA8BYX;6Q02P$"% ,4    "  I.0A78HN?2-L&   @
M,P  %0              @ 'R'   8V-C8RTR,#(S,#@P.%]P<F4N>&UL4$L!
M A0#%     @ *3D(5ZF1>.8%(   %CH! !@              ( ! "0  &-C
L8V,M,C R,S X,#AX97AX.3DQ+FAT;5!+!08     !0 % $H!   [1      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
